Frequently Asked Questions
The market is segmented based on , By Type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pan Colitis or Universal Colitis, and Fulminant Colitis), Drug Type (Anti-Inflammatory Drugs, Amino salicylates, Corticosteroids, Anti-TNF biologics, Immunosuppressant, Calcineurin Inhibitors and Other), Molecule Type (Small Molecules and Biologics), Route of Administration (Injectable and Oral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Store and Others) - Industry Trends and Forecast to 2030.
.
The Global Ulcerative Colitis Market size was valued at USD 7321.78 USD Million in 2023.
The Global Ulcerative Colitis Market is projected to grow at a CAGR of 5.7% during the forecast period of 2024 to 2030.
The major players operating in the market include Johnson & Johnson Services , Bayer AG, AbbVie , Merck & Co. , Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc., F. Hoffmann La Roche Ltd, Pfizer , Abbott, Astrazeneca, Sanofi, Allergan, CELGENE CORPORATION, Bristol,Myers Squibb Company, InDex Pharmaceuticals Holding AB.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa.
